Camptothecin and its analogs - An overview of their potential in cancer therapeutics

被引：31

作者：

Muggia, FM

Dimery, I

Arbuck, SG

机构：

[1] UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, DEV THERAPEUT PROGRAM, LOS ANGELES, CA 90033 USA

[2] NCI, INVEST DRUG BRANCH, CANC THERAPY EVALUAT PROGRAM, DIV CANC DIAG TREATMENT & CTR, BETHESDA, MD 20205 USA

来源：

CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT | 1996年 / 803卷

关键词：

D O I：

10.1111/j.1749-6632.1996.tb26391.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：213 / 223

页数：11

共 72 条

[1]

ANDO M, 1996, P AN M AM SOC CLIN, V15, P480

[2]

ANSARI RH, 1996, P AN M AM SOC CLIN, V15, P408

[3]

ARMSTRONG D, 1995, P AN M AM SOC CLIN, V14, P275

[4]

Beran M., 1995, Blood, V86, p337A

[5] ACTIVITY OF TOPOTECAN, A NEW TOPOISOMERASE-I INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS INVITRO [J].

BURRIS, HA ;

HANAUSKE, AR ;

JOHNSON, RK ;

MARSHALL, MH ;

KUHN, JG ;

HILSENBECK, SG ;

VONHOFF, DD .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (23) :1816-1820

[6]

CARMICHAEL J, 1996, P AN M AM SOC CLIN, V15, P283

[7]

CHEVALIER B, 1995, P AM SOC CLIN ONCOL, V14, pA737

[8]

CHEVALLIER B, 1995, P AN M AM SOC CLIN, V14, P267

[9]

DIMERY I, 1996, UNPUB PHASE 2 TRIAL

[10]

DOUILLARD JY, 1995, P AN M AM SOC CLIN, V14, P365

← 1 2 3 4 5 6 7 8 →